呼吸器内科

論文業績 2017 年 10 月～2018 年 9 月

原著
1. Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Arai T, Kumamoto T, Sanada H, Suetsugu T,Inoue H.Dual strands of miR-145 duplex(miR-145-5p and 145-3p)regulate oncogenes in lungadenocarcinoma pathogensis. J hum Genet. 2018 Oct; 63(10):1015-1028.
2. Tamura K, Matsumoto K, Fukuyama S, Kan-O K, Iahii Y, Tonai K, Tatsuta M, Enokizu A, InoueH, Nakanishi Y. Frequency-dependent airway hyperresponsiveness in a mouse model of emphysema
and allergic inflammation. Physiol Rep. 2019 Jan; 6(2):e13568.
3．Shirai T, Hirai K, Gon Y, Maruoka S, Mizumura K, Hikichi M, Holweg C, Itoh K, Inoue H,Hashimoto S. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD
overlap. J Allergy Clin Immunol Pract. 2019 Jan; 7(1):134-145.e1.
4. Uchida A, Seki N, Mizuno K, Misono S, Yamada Y, Kikkawa N, Sanada H, Kumamoto T,
Suetsugu T, Inoue H. Involvement of dual-strand of the miR-144 duplex and their targets in thepathogenesis lung squamous cell carcinoma. Cancer Science. 2019 Jan; 110(1):420-432.
5. Uchida A, Seki N, Mizuno K, Yamada Y, Misono S, Sanada H, Kikkawa N, Kumamoto T,Suetsugu T, Inoue H. Regulation of KIF2A by antitumor miR-451a inhibits cancer cellaggressiveness features in lung squamous cell carcinoma. Cancers. 2019 Feb; 11(2):258.
6. Suetsugu T, Koshizuka K, Seki N, Mizuno K, Okato A, Arai T, Misono S, Uchida A, Kumamoto T,Inoue H. Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-1505p,inhibits the aggressiveness of lung squamous cell carcinoma cells. Int Oncol. 2019 Mar;52(3):913-924.
7. Ogata H, Hirakawa Y, Matsumoto K, Hata J, Yoshida D, Fukuyama S, Inoue H, Kitazono T,Ninomiya T, Nakanishi Y. Trends in the prevalence of airflow limitation in a general Japanese
population: two serial cross-sectional surveys from the Hisayama Study. BMJ Open. 2019 Mar; 9(3):e023673.
8. Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Sanada H, Moriya S, Kikkawa T, Kumamoto T,Suetsugu T, Inoue H. Molecular pathogenesis of gene regulation by the miR-150 duplex: miR-150-3p
regulates TNS4 in lung adenocarcinoma. Cancers. 2019 Apr; 11(5):E601.

9. Harada Y, Suzuki T, Fukushige T, Kizuka Y, Yagi H, Yamamoto M, Kondo K, Inoue H, Kato K,Taniguchi N, Kanekura T, Dohmae N, Maruyama I. Generation of the heterogeneity of extracellular
vesicles by membrane organization and sorting machineries.Biochim Biophys Acta Gen Subj. 2019Apr; 1863(4):681-691.
10. Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E.
A retrospective cohort study evaluating healthcare resource utilization in patients with asthma inJapan. NPJ Prim Care Respir Med. 2019 Apr; 29(1):13.
11. Harada Y, Kizuka Y, Tokoro Y, Kondo K, Yagi H, Kato K, Inoue H, Taniguchi N, Maruyama I.Nglycome inheritance from cells to extracellular vesicles in B16 melanomas. FEBS Lett. 2019 May;
593(9):942-951.
12. Takeuchi K, Matsumoto K, Furuta M, Fukuyama S, Takeshita T, Ogata H, Suma S, Shibata Y,Shimazaki Y, Hata J, Ninomiya T, Nakanishi Y, Inoue H, Yamashita Y. Periodontitis is associatedwith chronic obstructive pulmonary disease. Journal of Dental Research. 2019 May; 98(5):534-540.
13．Sasaki J, Kawayama T, Yoshida M, Takahashi K, Fujii K, Machida K, Kinoshita T, Hoshino T,
the Kyushu Asthma Seminar Investigators. Adherence barriers to inhaled medicines in Japaneseolder patients with asthma evaluated using the "Adherence Starts with Knowledge 20" (ASK-20)
questionnaire. J Asthma. 2019 Jun; 56(6):632-641.
14．Aw M, Nair P, Salter B, Chen R, Machida K, Inman M, O'Byrne PM, Gauvreau GM, Sehmi R.
Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics. Allergy.
2019 Jul; 74(7):1397-1400.
13. Yamada Y, Kato M, Arai T, Sanada H, Uchida A, Misono S, Sakamoto S, Komiya A, Ichikawa T,Seki N. Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential
prognostic marker and therapeutic target. Mol Oncol. 2019 Sep; 13(9):1898-1912.
14．Sanada H, Seki N, Mizuno K, Misono S, Uchida A, Yamada Y, Moriya S, Kikkawa N, MachidaK, Kumamoto T, Suetsugu T, Inoue H. Involvement of dual strands of miR-143 (miR-143-5p andmiR-143-3p) and their target oncogenes in the molecular pathogenesis of lung adenocarcinoma. IntJ Mol Sci. 2019 Sep;20(18): pii E4482.

17．Machida K, Kawayama T, Kinoshita M, Ichinose M, Tsuda T, Takata S, Koto H, Yoshida M,Ashihara Y, Kawashima M, Suna H, Inoue H. Imidafenacin, An Orally Active Muscarinic Receptor
Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary
Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase IITrial. Int J Chron Obstruct Pulmon Dis. 2019 Sep 19; 14:2175-2184.

総説
1．町田健太朗，井上博雅：管理・治療 経過・予後．（【診断と治療の ABC 慢性閉塞性肺疾患(COPD)】第 4 章) 最新医学（別冊慢性閉塞性肺疾患）2018.11; 140:211-218.
1. 籾博晃，井上博雅：ACO の概念，疫学.(特集：喘息と COPD の合併（ACO）) 週刊 日本医事新報 No.4938 28-33，（2018 年 12 月 3 週号）
2. Takagi K, Machida K, Inoue H: Cellular mechanisms of Allergic airway inflammation. Advancesin Asthma. 2018 Dec:27-39.
3．Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, Buhl R, CruzAA, Fleming L, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Pedersen SE, Sheikh A,Yorgancioglu A, Boulet LP: GINA 2019: a fundamental change in asthma management: Treatmentof asthma with short-acting bronchodilators alone is no longer recommended for adults andadolescents. Eur Respir J. 2019 Jun 27; 53(6):pii1901046.
4. 三山英夫，籾博晃, 中塩屋二郎，井上博雅：喘息と慢性閉塞性肺疾患のオーバーラップ（ACO) 内科
2019.7; 124(1):1467-1470.
5. 坂上公太，髙木弘一，井上博雅：安定期の喘息治療の実際. 日本内科学会雑誌 2019.10; 8(6):11411148.
6. 堂嶽洋一，窪田幸司，籾博晃，井上博雅：COPD 早期発見を目指したスクリーニングツール.
(特集 COPD 早期発見の試み 監修 井上博雅）週刊日本医事新報. 2019.6; 4962:17-22.
7. 新村昌弘，籾博晃，井上博雅：特集 各科診療におけるステロイドの上手な使い方/各科におけるス
テロイド療法のノウハウ―呼吸器内科. 臨牀と研究. 2019.4; 96(4):18(412)-22(416).
8．井上博雅：重症喘息の診断と治療．日本内科学会雑誌．2019.9; 108(9):1860-1865.
9．坂上公太，町田健太朗，井上博雅：特集 免疫・アレルギー疾患における分子的標的薬の使い方

気管支喘息における臨床治験中の分子標的薬. 呼吸臨床． 2019.9; 3(9): e00073.
著書
Reddel HK, Bacharier LB, Bateman ED, Boulet LP ,Chris Brightling, Brusselle G, Buhl R,FitzGerald JM, Fleming L, Inoue H, Krishnan JA, Kevin Mortimer, Pedersen SE, Sheikh A, Ko FW:
1．Global Strategy for Asthma Management and Prevention．(2019 GINA, mainreport)
2．Pocket Guide for Asthma Management and Prevention.(2019 GINA, pocketguide)
3．Diagnosis and Management of Difficult-to-treat and Severe Asthma.
(2019 GINA, pocketguide for health professional)
4．町田健太郎，井上博雅．増悪期の管理と増悪予防

増悪の診断と重症度判定．
（第 6 章）呼吸器疾患

診断治療アプローチ COPD 慢性閉塞性肺疾患.2019.9:306-309.
症例
1. 隈元朋洋，冨岡勇也，松山洋美，鵜木泰自，谷川健悟，堂嶽洋一，三山英夫，籾博晃，佐藤雅美，井上博雅：若年男性に発症した気管支原発粘表皮癌の１例. 気管支学. 2019.3; 41(2):193-197.
2. Tanigawa K, Mizuno K, Kamenohara Y, Unoki T, Misono S, Inoue H: Effect of bevacizumab onbrain radiation necrosis in anaplastic lymphoma kinase-positive lung cancer. Respirology CaseReports. 2019 May; 7(7):e00454.
3. 窪田幸司，水野圭子，安田俊介，福田宏正，井上博雅: ニボルマブが奏功した進行肺癌と食道癌の同時性重複癌の 1 例. 日本呼吸器学会誌. 2019.7; 8(4):273-277.
その他
1. (座談会)井上博雅，Christopher Brightling，髙橋浩一郎，松本幸一郎，古藤洋：Type2 炎症から見た重症喘息治療の意義. デュピクセント🄬医療関係者向け情報（サノフィ株式会社）